Two-phase [11C]l-methionine PET in childhood brain tumors

doi:10.1016/0887-8994(90)90057-8

Pediatric Neurology

Volume 6, Issue 3, May–June 1990, Pages 163-170

https://doi.org/10.1016/0887-8994(90)90057-8 Get rights and content

Abstract

Thirteen children (1.8–15.8 years of age) with brain tumors were studied with [¹¹C]l-methionine positron emission tomography (METPET). Patients were injected intravenously with tracer before a baseline PET scan was obtained. To assess the sensitivity of [¹¹C]l-methionine uptake to competitive inhibition, 10 patients received oral l-phenylalanine (100 mg/kg); 1 hour later, a second METPET was obtained. Subjective assessment of [¹¹C]l-methionine uptake closely paralleled results of quantitative examination (r = 0.81). [¹¹C]l-methionine uptake in tumor-containing brain was increased in 11 patients (mean ratio of [¹¹C] radioactivity in tumor to normal brain: 1.5 ± 0.57; range: 1.13–2.98). Increased tracer uptake occurred in ependymomas (3), medulloblastoma (1), and astrocytomas (5), but was less intense in low-grade tumors. l-phenylalanine reduced l-methionine uptake (25–69%) in 70% of studies. l-methionine uptake was not sensitive to competitive inhibition in brain radiation injury. Two-phase METPET is of potential value in difficult clinical situations evident in children with brain tumors, including the differential diagnosis of tumor recurrence and cerebral radiation injury.

References (27)

RG Selker et al.
Pathologic correlation of CT ring enhancement in recurrent, previously treated gliomas
Surg Neurol
(1982)
KM Hargreaves et al.
Neutral amino acid transport across the human blood-brain barrier
J Biol Chem
(1988)
A Gjedde
Calculation of glucose phosphorylation from brain uptake of glucose analogs in vivo: A re-examination
Brain Res Rev
(1982)
K Winston et al.
Cerebellar gliomas in children
Natl Cancer Inst Monogr
(1977)
PJ Duffner et al.
Recent developments in pediatric neuro-oncology
Cancer
(1986)
M Prados et al.
Malignant supratentorial glioma in childhood
Pediatr Neurosci
(1987)
JL Finlay et al.
Brain tumors in children, 1. Advances in diagnosis
Am J Pediatr Hematol Oncol
(1987)
M Bergström et al.
Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [⁶⁸Gallium] EDTA, [¹¹C] glucose, and [¹¹C] methionine
J Comput Assist Tomogr
(1983)
GC Dooms et al.
Brain radiation lesions: MR imaging
Radiology
(1986)
DA Graeb et al.
Transient early computed tomographic changes mimicking tumor progression after brain tumor irradiation
Radiology
(1982)

K Huebner et al.

Brain tumor imaging by positron emission computed tomography using C-11 labeled amino acids

J Comput Assist Tomogr

(1982)

K Ericson et al.

Positron emission tomography with ([¹¹C]methyl)l-methionine, [¹¹C]d-glucose, and [68Ga]EDTA in supratentorial tumors

J Comput Assist Tomogr

(1985)

LA O'Tuama et al.

Quantitative imaging of neutral amino acid transport by human brain tumors

J Cereb Blood Flow Metab

(1987)

Cited by (59)

Positron emission tomography imaging in primary brain tumors
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4
This article will provide a wide and comprehensive overview of Positron Emission Tomography (PET) radiopharmaceuticals used in primary brain tumors (PBT) management. PBT is a group of tumors arising from the central nervous system, and they present histopathological and molecular heterogeneity. Contrast-enhanced magnetic resonance imaging (MRI) is the gold standard imaging tool for diagnosis and treatment evaluation of PBT (providing excellent anatomic details), but this imaging technique may show some pitfalls and limitations. Furthermore, contrast enhancement of MRI can be often altered by corticosteroid or antiangiogenic or immunotherapeutic drugs that modify tumor vascular permeability. Molecular imaging with PET provides metabolic and functional information regarding tumoral processes (for instance, glucose metabolism, amino acids uptake, cell proliferation, or membrane synthesis) and aids in complementing MRI in the evaluation of patients with PBT. In standard clinical practice, PET imaging has a useful role in the primary diagnosis, especially regarding the tumor grading and the definition of biopsy site: moreover, PET imaging has a central role in the diagnosis of tumor recurrence, in the distinction between tumor growth and post-treatment effects (such as pseudoprogression or radionecrosis) and in the disease and therapy monitoring. In this article the most used radiopharmaceuticals in the management of PBT will be described (explaining their usefulness as well as their limitations), such as 18F-Fluorodeoxyglucose (18F-FDG), 11C-methyl-l-methionine (11C-MET), 3,4-dihydroxy-6-18F-fluoro-l-phenylalanine (18F-FDOPA), Fluorine-18 fluoroethyltyrosine (18F-FET), Radiopharmaceuticals for imaging of tumor hypoxia, ⁶⁸Ga-Dota-peptides, radiolabeled choline, ⁶⁸Ga Prostate-Specific Membrane Antigen (⁶⁸Ga-PSMA), and 3 0 -deoxy-3 0-18F-Fluoro-fluorothymidine (18F-FLT).
New PET radiopharmaceuticals for cancer imaging
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4
The idea of personalized medicine has been growing in clinical research for the past decade. Molecular imaging, first introduced in 2001 as a multidisciplinary practice, is undoubtedly playing an important role in the transition of conventional medical practice. When compared to optical imaging modalities, positron emission tomography (PET) is highly sensitive and it has the ability to obtain absolute imaging quantification after corrections for photon attenuation and scattering. In addition, due to the unique feature to image ¹¹C, ¹³N, or ¹⁵O labeled compounds naturally in the body, the role of PET has been well-established in the field of molecular imaging. Our aim in this article is therefore to provide an overview of the recent advances in PET radiopharmaceuticals and their clinical application in oncology.
Liponeurocytoma: Systematic Review of a Rare Entity
2018, World Neurosurgery
Citation Excerpt :
Giammarile et al.82 observed a tumor/normal tissue ratio of around 1 (range, 0.9–1.8) and higher accumulation (range, 1.4–5.9) on FDG and [11C]methionine PET. Contrary to the FDG and [11C]methionine PET in liponeurocytomas and central neurocytomas, ependymomas and medulloblastomas show higher FDG and [11C]methionine uptake in PET examinations,83-86 whereas dysembryoplastic neuroepithelial tumors show lower and normal to slightly higher uptake compared with normal cortex on those studies.87 Horstmann et al.88 observed the genetic profile of the cerebellar liponeurocytoma to differentiate the cerebellar liponeurocytoma genetically from the cerebellar medulloblastoma and the central neurocytoma after collecting 20 tumor samples from 20 patients worldwide.
Liponeurocytoma is a rare benign tumor of the central nervous system, which develops mainly in adult patients within the posterior fossa. The World Health Organization has categorized this entity in its last classification of 2016 as a benign grade II tumor. Histopathologic characteristics contain neuronal and variable astrocytic differentiation with foci of lipomatous distinction. Only a few case reports and case series have been reported and the knowledge of this tumor is limited. General treatment guidelines do not exist. The aim of this study was to analyze the literature to create treatment guidelines.
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed to search existing online databases between January 1, 1978 and May 15, 2018.
A systematic review of the literature found 73 patients (40 female, 33 male) with liponeurocytoma, in 59 of whom (80.8%) the disease occurred in the posterior fossa. The Ki-67/MIB-1 proliferation index was described in 58 patients, showing a mean value of 3.73% ± 4.01%. Follow-up was performed in 49 patients, with a median length of 52.02 ± 50.52 months, showing tumor recurrence in 14 patients (28.57%). Tumor recurrence was observed in only 1 patient (1/12, 8.33%) after adjuvant radiotherapy, whereas tumor recurrence was seen in 13/29 patients (44.83%) who did not receive adjuvant radiotherapy.
Liponeurocytomas are rare benign tumors, occurring mainly in the cerebellum. The therapy of choice is surgery. Postoperative radiotherapy seems to decrease the risk of tumor recurrence and should be offered to the patient.
Imaging brain tumors with PET, SPECT, and ultrasonography
2012, Handbook of Clinical Neurology
Among various physiological and biochemical imaging modalities, positron emission tomography (PET) provides quantitative measures of energy metabolism, solute and drug transport, and cell proliferation. For clinical applications in patients with brain tumors, radiolabeled deoxyglucose ([¹⁸F]-2-fluoro-2-deoxy-d-glucose, FDG) and amino acids (e.g., [¹¹C]methionine, O-2-[¹⁸F]fluoroethyl-l-tyrosine) are validated and widely available. To localize metabolic alterations accurately, particularly within heterogeneous lesions, the coregistration of PET images with structural imaging such as magnetic resonance imaging (MRI) is mandatory. In the diagnostic setting, PET with FDG allows the grading of gliomas, the detection of malignant transformation, and the differentiation of recurrent malignant glioma from radiation-induced necrosis. Amino acids are established to identify metabolically active regions within suspected low-grade gliomas that are suitable for stereotactic biopsy. Amino acids may also be used for treatment evaluation, as metabolic responses (PET) may occur several months before tumor volume reductions (MRI). Therefore, PET allows treatment decisions to be tailored for individual patients, and efficacy and safety to be optimized. With its broad range of diagnostic applications, PET is well suited to be integrated into multidisciplinary clinical trials and research protocols.
Molecular Imaging (PET) of Brain Tumors
2009, Neuroimaging Clinics of North America
PET and MR Imaging of Brain Tumors
2008, PET Clinics
Citation Excerpt :
MET-PET has been studied to determine its value in a variety of roles in the evaluation of neoplasms, including detection, delineation of tumor, grading, prognosis, and effectiveness of therapy. MET accumulates in gliomas, as demonstrated by multiple prior studies, and MET-PET has repeatedly demonstrated that it is a very sensitive tool for detection of brain neoplasms.39,82–86 The sensitivities for malignant neoplasms have ranged from 61% to 97%, with higher rates for higher grade neoplasms.85
A better understanding of tumorigenesis is crucial for the development of specific molecular therapies that specifically target the neoplasm and reduce patient morbidity and mortality. PET measures a wide range of physiologic processes critical for understanding the pathophysiology of brain neoplasms with high sensitivity. Continuous developments in PET provide new insights into the diagnosis, classification, and pathophysiology of brain neoplasms. As such, PET has played an increasingly important role in the staging of brain neoplasms, image-guided therapy planning, and treatment monitoring. This article addresses the most commonly used agents in PET imaging of brain tumors.

View all citing articles on Scopus

^☆: Supported in part by NIH Grants CA 32846 and NS 15080 and by the Children's Cancer foundation.

View full text

Original articleTwo-phase [11C]l-methionine PET in childhood brain tumors☆

Abstract

Surg Neurol

J Biol Chem

Brain Res Rev

Cerebellar gliomas in children

Natl Cancer Inst Monogr

Recent developments in pediatric neuro-oncology

Cancer

Malignant supratentorial glioma in childhood

Pediatr Neurosci

Brain tumors in children, 1. Advances in diagnosis

Am J Pediatr Hematol Oncol

Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Gallium] EDTA, [11C] glucose, and [11C] methionine

J Comput Assist Tomogr

Brain radiation lesions: MR imaging

Radiology

Transient early computed tomographic changes mimicking tumor progression after brain tumor irradiation

Radiology

Brain tumor imaging by positron emission computed tomography using C-11 labeled amino acids

J Comput Assist Tomogr

Positron emission tomography with ([11C]methyl)l-methionine, [11C]d-glucose, and [68Ga]EDTA in supratentorial tumors

J Comput Assist Tomogr

Quantitative imaging of neutral amino acid transport by human brain tumors

J Cereb Blood Flow Metab

Original article
Two-phase [¹¹C]l-methionine PET in childhood brain tumors☆

Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [⁶⁸Gallium] EDTA, [¹¹C] glucose, and [¹¹C] methionine

Positron emission tomography with ([¹¹C]methyl)l-methionine, [¹¹C]d-glucose, and [68Ga]EDTA in supratentorial tumors